• 18 October 2016

     Additional analyses of data from COLLECT – a clinical study of InDex Pharmaceuticals Holding AB’s (publ) lead drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis – was orally presented and met with great interest at the United European Gastroenterology Week (UEGW) 2016 in Vienna.

  • 12 October 2016

    Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announces the appointment of Paul Fry as Chief Financial Officer. 

  • 7 October 2016

    JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated heart-valve technology, and a company that is committed to making transcatheter aortic valve replacement (TAVR) available to the broadest spectrum of patients with aortic valve disease, today announced the appointment of veteran medical device executive Greg Mirigian as Vice President of Research and Development, effective immediately. Mirigian will be based in Irvine, Calif. at JenaValve’s corporate headquarters. 

  • 6 October 2016

    London, UK, 6 October 2016: TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and eye, announced today that the first patients have been dosed in its Phase 2a proof-of-concept study to evaluate the safety, tolerability and efficacy of a rectal formulation of TOP1288 in symptomatic ulcerative colitis (UC) patients with moderate to severe disease activity.

  • 26 September 2016

    Sonendo®, Inc., — The developer of a breakthrough technology that offers an alternative to standard root canal therapy, today announced the appointment of John (Jack) Glenn as Chief Financial Officer. Mr. Glenn brings 25 years of financial leadership experience within public and private companies in the life science industry.